Historically, the clinical research community has been slow to adopt decentralized or hybrid trial models. There are many overall benefits of decentralized/hybrid trials and remote monitoring: increased enrollment and retention of patients in clinical studies, the reduction of administrative burdens on sponsors and investigators and the ability for patients to receive treatments from their community providers without compromising study quality or data integrity.
The COVID-19 pandemic has made these benefits even more obvious, and as travel restrictions, social distancing and the overall strain on the healthcare system became more evident, the FDA updated regulations to fast-track research, openly recognizing the value of alternative technology such as virtual trial capabilities in clinical research.
This webinar will explore how COVID-19 pushed the industry to adapt to tech-enabled solutions for patients and sponsors.
Join Eli Alford as he shares how Elligo’s healthcare-enabling approach was able to respond rapidly to the challenges presented by COVID-19 by effectively supporting and staffing drive-through COVID-19 test sites while also maintaining support for active trials across their network.
Eli Alford, MS, Chief Operating Officer, Elligo Health Research
Eli Alford brings nearly 40 years of leadership experience to Elligo, along with a strong track record of increasing productivity and improving organizational and individual effectiveness.
Prior to Elligo, Alford was COO of Schulman IRB for six years, leading one of the largest independent commercial institutional review boards in North America. There, he worked with more than 600 study sponsors, including most of the top 50 global biopharma companies, and thousands of principal investigators. During Alford’s tenure, Schulman navigated through private equity ownership changes and a successful merger to create Advarra.
Before Schulman, Alford served in successive roles in proposals, operations management, business process improvement and corporate development at INC Research (now Syneos Health). During his four years there, INC grew from 800 primarily North America-based employees to 5,000 employees on six continents.
Alford earned a BA from the Virginia Military Institute, an MS from the University of Southern California and was a National Security Fellow at the Harvard Kennedy School. He served a distinguished US Army career of nearly 26 years in a broad array of command and staff roles ranging from small combat arms units to multiple Pentagon assignments.Message Presenter
Who Should Attend?
- Pharma, biotech, medical device
What You Will Learn
In this webinar, attendees will learn about:
- The importance of decentralized/hybrid trial models and remote monitoring in current and future studies
- What regulatory changes were brought into effect during the pandemic that will change the future of research
- How innovations in technology were used to support clinical research during the pandemic in order to keep trials on track and make future trials more efficient
Elligo Health Research®
Elligo Health Research, a healthcare-enabling research organization, uses electronic health records and the trusted patient and physician relationship to ensure all patients have access to clinical research as a care option. Powered by our Goes Direct® approach and novel IntElligo Research Stack™ clinical technology, our team provides access to the best healthcare experts, patients, and research technologies. We engage physicians and patients who otherwise would not participate in clinical research and accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Learn more at elligodirect.com.